Dive Brief:
- The GSK/Adaptimmune partnership will focus on developing treatments for multiple myeloma and other cancers.
- The main target will be T cell receptors.
- Clinical proof of concept is anticipated by 2016.
Dive Insight:
The collaboration between the two companies will focus on developing therapies not only for multiple myeloma, but also for melanoma, sarcoma and ovarian cancer. Adaptimmune could gross $350 million over a 7-year period.